At last check, in the pre-market trading session, ADiTx Therapeutics Inc. (ADTX) stock plunged by -8.75% to $2.92. ADTX stock gained 11.89% when it previously closed at $3.20. The ADTX stock volume traded 3.31 million shares. In the past week, the shares moved up by 13.48%. In the past three and six months, the stock shed -1.84% and added 60.00% respectively. Furthermore, ADiTx Therapeutics is currently valued in the market at $43.97 million and has 12.34 million outstanding shares.
The life sciences company’s background
ADiTx Therapeutics, Inc., a life sciences company that focuses on the development technologies for increasing and enhancing the health of the immune system. It is done so by using ADiTxstock’s immune monitoring and reprogramming system. This system is known as AditxtScore which allows individuals to monitor their profile for immune system and be aware of any incoming attacks done by or to the immune system.
Aditx Therapeutics is planning to build high capacity AditxtScoreTM Center
On 3rd May 2021, the Aditx Therapeutics Inc. announced that it has planned a project to build a high-capacity AditxtScoreTM Center. The center will be constructed in the second half of 2021 and is aimed to be built in in Richmond VA.
The new project will take up to three years for it to be scaled up. This scaling-up measurement consists of laboratory equipment, construction, and the integration of new jobs into the immune system monitoring center.
The application of this infrastructural-scaled innovative product system is vast in the field of health and biotechnology. The Aditxtscore system essentially provides a platform where the whole profiling of the immune system can be done for the patients using the biomarkers of immunity. This will allow the patient to be aware of what sort of various attacks the immune system is responsible for or fighting against.
The Aditxtscore system is being eyed by the company as well as the investors for its capability to be used specifically for COVID-19 detection. The system does so by detecting the antibodies and eliminating the antibodies against SARS-CoV-2 antigens.
The choice of location being Richmond is for its experienced and skilled workforce, more than 300 of which is expected to be given job in the center over the next three years. Furthermore, the targeted capital investment in the facility is over $31.5 million over the scale of three years. This expansion will allow an expected estimate of 10 million reports projected by the Aditxtscore center.
The new center allows for ADTX to expand its operations
The company is in collaboration with Virginia Economic Development Partnership. The VEDP created a program known as Virginia Accelerator Program which will help in the job creation aspect for the Aditxtscore monitoring center. The program will also target the Virginia Community College System and other high education partners.
This step is an expansion in the infrastructural growth and operations of the ADTX stock. Furthermore, the pioneer program already has a high demand that surged due to COVID-19 in the pandemic, thus the demand for the ADTX’s product offering and future partnerships potential with government and private institutions, ticks off the fundamental metrics of ADTX stock positively.